GLP-1 Drug Users Are Nearly 6 Times More Likely to Have Food in Their Stomach Before Surgery Despite Fasting
GLP-1 agonist therapy was associated with a 5.8-fold increased odds of residual gastric contents in fasting patients undergoing endoscopy, with 19% showing visible food versus 5% in controls.
Quick Facts
What This Study Found
GLP-1 agonist therapy was associated with an adjusted odds ratio of 5.8 (95% CI 1.7-19.3, p=0.004) for residual gastric contents in fasting patients, with 19% of GLP-1 users showing visible food at endoscopy versus 5% of controls.
Key Numbers
90 procedures in GLP-1 users compared to matched controls. Study period: 2019-2023.
How They Did This
Historical cohort study reviewing EGD records (2019-2023). 90 procedures in patients on GLP-1 agonists (GLP group) compared to 102 procedures in patients who started GLP-1 therapy within 1,000 days after their EGD (control). Excluded: emergent procedures, combined EGD/colonoscopy, known gastroparesis, previous gastric surgery. Confounder-adjusted generalized linear mixed effect model.
Why This Research Matters
With millions of people now taking GLP-1 drugs, this is a critical safety signal for anesthesia and procedural medicine. Retained gastric contents during sedation can lead to aspiration pneumonia — a potentially fatal complication. Patients and providers need to be aware that standard fasting guidelines may not be sufficient for GLP-1 drug users.
The Bigger Picture
This study adds to growing evidence that GLP-1 drugs significantly delay gastric emptying — a feature that helps with appetite suppression but creates procedural risks. The American Society of Anesthesiologists has already updated guidelines to recommend holding GLP-1 drugs before elective procedures, but practice varies widely. As GLP-1 prescriptions explode, standardized pre-procedural protocols are urgently needed.
What This Study Doesn't Tell Us
Retrospective design with relatively small sample sizes. The control group (future GLP-1 users) may differ from the GLP group in ways that affect gastric emptying. Documentation of gastric contents may vary by endoscopist. The fasting duration was comparable but specific timing of last GLP-1 dose was not captured. The study cannot establish how long before a procedure GLP-1 drugs should be held.
Questions This Raises
- ?How many days before an elective procedure should GLP-1 drugs be held to normalize gastric emptying?
- ?Should GLP-1 drug users undergo additional pre-procedural assessment (like point-of-care gastric ultrasound) before sedation?
- ?Does the risk differ between weekly (semaglutide) and daily (liraglutide) GLP-1 formulations?
Trust & Context
- Key Stat:
- 5.8× higher odds of retained food GLP-1 drug users had nearly 6 times the risk of having visible gastric contents despite standard fasting before endoscopy
- Evidence Grade:
- Moderate evidence from a well-designed historical cohort study. Small sample size limits precision, but the effect size is large and clinically significant. Findings align with known GLP-1 pharmacology.
- Study Age:
- Published in 2024, addressing a timely safety concern as GLP-1 drug prescriptions grow rapidly worldwide.
- Original Title:
- Association of glucagon-like peptide receptor 1 agonist therapy with the presence of gastric contents in fasting patients undergoing endoscopy under anesthesia care: a historical cohort study.
- Published In:
- Canadian journal of anaesthesia = Journal canadien d'anesthesie, 71(7), 958-966 (2024)
- Authors:
- Wu, Fei(2), Smith, Matthew R, Mueller, Ariel L, Klapman, Seth A, Everett, Lucinda L, Houle, Timothy, Kuo, Braden, Hobai, Ion A
- Database ID:
- RPEP-09540
Evidence Hierarchy
Frequently Asked Questions
Should I stop my GLP-1 drug before a medical procedure?
You should discuss this with your prescribing doctor and your anesthesiologist. The American Society of Anesthesiologists has recommended holding GLP-1 drugs before elective procedures, but specific guidance (how many days before) is still evolving. This study shows that standard overnight fasting may not be enough to empty the stomach in GLP-1 users, so additional precautions may be needed. Never stop a medication without medical guidance.
Why is retained stomach food during sedation dangerous?
When you're sedated or under anesthesia, your normal protective reflexes (like the gag reflex) are suppressed. If there's food or liquid in your stomach, it can flow backward into your esophagus and get inhaled into your lungs — this is called aspiration. Aspiration can cause pneumonia, respiratory failure, or in severe cases, death. That's why fasting before procedures is so important, and why GLP-1 drugs' effect on slowing stomach emptying is a significant safety concern.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09540APA
Wu, Fei; Smith, Matthew R; Mueller, Ariel L; Klapman, Seth A; Everett, Lucinda L; Houle, Timothy; Kuo, Braden; Hobai, Ion A. (2024). Association of glucagon-like peptide receptor 1 agonist therapy with the presence of gastric contents in fasting patients undergoing endoscopy under anesthesia care: a historical cohort study.. Canadian journal of anaesthesia = Journal canadien d'anesthesie, 71(7), 958-966. https://doi.org/10.1007/s12630-024-02719-z
MLA
Wu, Fei, et al. "Association of glucagon-like peptide receptor 1 agonist therapy with the presence of gastric contents in fasting patients undergoing endoscopy under anesthesia care: a historical cohort study.." Canadian journal of anaesthesia = Journal canadien d'anesthesie, 2024. https://doi.org/10.1007/s12630-024-02719-z
RethinkPeptides
RethinkPeptides Research Database. "Association of glucagon-like peptide receptor 1 agonist ther..." RPEP-09540. Retrieved from https://rethinkpeptides.com/research/wu-2024-association-of-glucagonlike-peptide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.